Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.

Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW.

J Urol. 2005 Sep;174(3):919-22.

PMID:
16093988
2.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

3.

Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.

Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.

J Urol. 2006 Aug;176(2):554-8.

PMID:
16813888
4.
5.

Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.

Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW, Freedland SJ.

J Urol. 2006 Aug;176(2):515-9.

PMID:
16813880
6.

Obesity and capsular incision at the time of open retropubic radical prostatectomy.

Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI, Partin AW.

J Urol. 2005 Nov;174(5):1798-801; discussion 1801.

PMID:
16217290
7.

The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.

Freedland SJ, Mangold LA, Walsh PC, Partin AW.

J Urol. 2005 Oct;174(4 Pt 1):1276-81; discussion 1281; author reply 1281.

PMID:
16145392
8.

Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.

Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ; Search Database Study Group.

J Urol. 2004 Aug;172(2):520-4.

PMID:
15247719
9.

Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group.

Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, Terris MK.

J Clin Oncol. 2004 Feb 1;22(3):446-53. Epub 2003 Dec 22.

PMID:
14691122
10.

Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.

Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y.

Eur Urol. 2006 Feb;49(2):293-302. Epub 2005 Dec 20.

PMID:
16387412
11.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
12.

Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.

Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, Gonzalgo ML.

J Urol. 2007 Oct;178(4 Pt 1):1311-5. Epub 2007 Aug 16.

PMID:
17698095
13.

Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.

Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT.

J Urol. 2005 Sep;174(3):903-7.

PMID:
16093984
14.

Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?

Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ.

J Urol. 2006 Dec;176(6 Pt 1):2453-8; discussion 2458.

PMID:
17085127
15.

Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ.

J Urol. 2007 Jan;177(1):102-6; discussion 106.

PMID:
17162013
16.

Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy.

Tomaszewski JJ, Chen YF, Bertolet M, Ristau BT, Woldemichael E, Nelson JB.

Urology. 2013 May;81(5):992-6. doi: 10.1016/j.urology.2012.10.080. Epub 2013 Feb 28.

PMID:
23453649
17.

Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ.

Urology. 2000 Nov 1;56(5):807-11.

PMID:
11068307
18.

Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.

BaƱez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ.

J Urol. 2009 Aug;182(2):491-6; discussion 496-8. doi: 10.1016/j.juro.2009.04.007. Epub 2009 Jun 13.

PMID:
19524974
19.

Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.

Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA.

Clin Cancer Res. 2005 Apr 15;11(8):2883-8.

20.

Supplemental Content

Support Center